Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer

BACKGROUND: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. MATERIALS & METHODS: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Murillo, Serafin Morales, Cudos, Ariadna Gasol, Rodriguez, Joel Veas, Morales, Carles Canosa, Olivé, Jordi Melé, Villellas, Felip Vilardell, Sanchez Guzman, Douglas Rene, Martínez, Edelmiro Iglesias, Salvia, Antonieta Salud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849928/
https://www.ncbi.nlm.nih.gov/pubmed/33552547
http://dx.doi.org/10.2144/fsoa-2020-0146
Descripción
Sumario:BACKGROUND: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. MATERIALS & METHODS: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer. DISCUSSION: Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.

Ejemplares similares